Glucose transporter-1 in pulmonary neuroendocrine carcinomas: Expression and survival analysis

Irem H. Ozbudak, Konstantin Shilo, Fabio Tavora, Negar Rassaei, Wei Sing Chu, Junya Fukuoka, Jin Jen, William D. Travis, Teri J. Franks

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Glucose transporter-1 (GLUT-1) mediates the transport of glucose across the cellular membrane. Its elevated levels and/or activation have been shown to be associated with malignancy. The aim of this study was to investigate GLUT-1 expression in pulmonary neuroendocrine carcinomas. Tissue microarray-based samples of 178 neuroendocrine carcinomas, including 48 typical carcinoids, 31 atypical carcinoids, 27 large cell neuroendocrine carcinomas and 72 small cell carcinomas from different patients, were studied immunohistochemically for GLUT-1 expression. Forty-seven percent (75/161) of pulmonary neuroendocrine carcinomas were immunoreactive with GLUT-1. GLUT-1 was observed in 7% (3/46) of typical carcinoid, 21% (6/29) of atypical carcinoid, 74% (17/23) of large cell neuroendocrine carcinoma and 78% (49/63) of small cell carcinoma. GLUT-1 expression correlated with increasing patient age (P0.01) and with neuroendocrine differentiation/tumor type (P 0.001), but not with gender, tumor size or stage. GLUT-1 expression was seen in a characteristic membranous pattern of staining along the luminal borders or adjacent to necrotic areas. GLUT-1 expression was associated with an increased risk of death for neuroendocrine carcinomas as a group (risk ratio2.519; 95% confidence interval1.519 4.178; P 0.001) and carcinoids (risk ratio4.262; 95% confidence interval1.472 12.343; P0.01). In conclusion, GLUT-1 is expressed in approximately half of the pulmonary neuroendocrine carcinomas and shows a strong correlation with neuroendocrine differentiation/grade, but not with other clinicopathologic variables. Further studies appear plausible to elucidate the prognostic significance of GLUT-1 expression in pulmonary carcinoids.

Original languageEnglish (US)
Pages (from-to)633-638
Number of pages6
JournalModern Pathology
Volume22
Issue number5
DOIs
StatePublished - May 2009
Externally publishedYes

Fingerprint

Neuroendocrine Carcinoma
Facilitative Glucose Transport Proteins
Survival Analysis
Carcinoid Tumor
Lung
Large Cell Carcinoma
Small Cell Carcinoma
Neuroendocrine Tumors
Neoplasms
Staining and Labeling

Keywords

  • Carcinoid
  • GLUT-1
  • Lung
  • Neuroendocrine carcinoma
  • Survival

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Ozbudak, I. H., Shilo, K., Tavora, F., Rassaei, N., Chu, W. S., Fukuoka, J., ... Franks, T. J. (2009). Glucose transporter-1 in pulmonary neuroendocrine carcinomas: Expression and survival analysis. Modern Pathology, 22(5), 633-638. https://doi.org/10.1038/modpathol.2009.6

Glucose transporter-1 in pulmonary neuroendocrine carcinomas : Expression and survival analysis. / Ozbudak, Irem H.; Shilo, Konstantin; Tavora, Fabio; Rassaei, Negar; Chu, Wei Sing; Fukuoka, Junya; Jen, Jin; Travis, William D.; Franks, Teri J.

In: Modern Pathology, Vol. 22, No. 5, 05.2009, p. 633-638.

Research output: Contribution to journalArticle

Ozbudak, IH, Shilo, K, Tavora, F, Rassaei, N, Chu, WS, Fukuoka, J, Jen, J, Travis, WD & Franks, TJ 2009, 'Glucose transporter-1 in pulmonary neuroendocrine carcinomas: Expression and survival analysis', Modern Pathology, vol. 22, no. 5, pp. 633-638. https://doi.org/10.1038/modpathol.2009.6
Ozbudak, Irem H. ; Shilo, Konstantin ; Tavora, Fabio ; Rassaei, Negar ; Chu, Wei Sing ; Fukuoka, Junya ; Jen, Jin ; Travis, William D. ; Franks, Teri J. / Glucose transporter-1 in pulmonary neuroendocrine carcinomas : Expression and survival analysis. In: Modern Pathology. 2009 ; Vol. 22, No. 5. pp. 633-638.
@article{c105d900bcf1410383e682621babe0e0,
title = "Glucose transporter-1 in pulmonary neuroendocrine carcinomas: Expression and survival analysis",
abstract = "Glucose transporter-1 (GLUT-1) mediates the transport of glucose across the cellular membrane. Its elevated levels and/or activation have been shown to be associated with malignancy. The aim of this study was to investigate GLUT-1 expression in pulmonary neuroendocrine carcinomas. Tissue microarray-based samples of 178 neuroendocrine carcinomas, including 48 typical carcinoids, 31 atypical carcinoids, 27 large cell neuroendocrine carcinomas and 72 small cell carcinomas from different patients, were studied immunohistochemically for GLUT-1 expression. Forty-seven percent (75/161) of pulmonary neuroendocrine carcinomas were immunoreactive with GLUT-1. GLUT-1 was observed in 7{\%} (3/46) of typical carcinoid, 21{\%} (6/29) of atypical carcinoid, 74{\%} (17/23) of large cell neuroendocrine carcinoma and 78{\%} (49/63) of small cell carcinoma. GLUT-1 expression correlated with increasing patient age (P0.01) and with neuroendocrine differentiation/tumor type (P 0.001), but not with gender, tumor size or stage. GLUT-1 expression was seen in a characteristic membranous pattern of staining along the luminal borders or adjacent to necrotic areas. GLUT-1 expression was associated with an increased risk of death for neuroendocrine carcinomas as a group (risk ratio2.519; 95{\%} confidence interval1.519 4.178; P 0.001) and carcinoids (risk ratio4.262; 95{\%} confidence interval1.472 12.343; P0.01). In conclusion, GLUT-1 is expressed in approximately half of the pulmonary neuroendocrine carcinomas and shows a strong correlation with neuroendocrine differentiation/grade, but not with other clinicopathologic variables. Further studies appear plausible to elucidate the prognostic significance of GLUT-1 expression in pulmonary carcinoids.",
keywords = "Carcinoid, GLUT-1, Lung, Neuroendocrine carcinoma, Survival",
author = "Ozbudak, {Irem H.} and Konstantin Shilo and Fabio Tavora and Negar Rassaei and Chu, {Wei Sing} and Junya Fukuoka and Jin Jen and Travis, {William D.} and Franks, {Teri J.}",
year = "2009",
month = "5",
doi = "10.1038/modpathol.2009.6",
language = "English (US)",
volume = "22",
pages = "633--638",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Glucose transporter-1 in pulmonary neuroendocrine carcinomas

T2 - Expression and survival analysis

AU - Ozbudak, Irem H.

AU - Shilo, Konstantin

AU - Tavora, Fabio

AU - Rassaei, Negar

AU - Chu, Wei Sing

AU - Fukuoka, Junya

AU - Jen, Jin

AU - Travis, William D.

AU - Franks, Teri J.

PY - 2009/5

Y1 - 2009/5

N2 - Glucose transporter-1 (GLUT-1) mediates the transport of glucose across the cellular membrane. Its elevated levels and/or activation have been shown to be associated with malignancy. The aim of this study was to investigate GLUT-1 expression in pulmonary neuroendocrine carcinomas. Tissue microarray-based samples of 178 neuroendocrine carcinomas, including 48 typical carcinoids, 31 atypical carcinoids, 27 large cell neuroendocrine carcinomas and 72 small cell carcinomas from different patients, were studied immunohistochemically for GLUT-1 expression. Forty-seven percent (75/161) of pulmonary neuroendocrine carcinomas were immunoreactive with GLUT-1. GLUT-1 was observed in 7% (3/46) of typical carcinoid, 21% (6/29) of atypical carcinoid, 74% (17/23) of large cell neuroendocrine carcinoma and 78% (49/63) of small cell carcinoma. GLUT-1 expression correlated with increasing patient age (P0.01) and with neuroendocrine differentiation/tumor type (P 0.001), but not with gender, tumor size or stage. GLUT-1 expression was seen in a characteristic membranous pattern of staining along the luminal borders or adjacent to necrotic areas. GLUT-1 expression was associated with an increased risk of death for neuroendocrine carcinomas as a group (risk ratio2.519; 95% confidence interval1.519 4.178; P 0.001) and carcinoids (risk ratio4.262; 95% confidence interval1.472 12.343; P0.01). In conclusion, GLUT-1 is expressed in approximately half of the pulmonary neuroendocrine carcinomas and shows a strong correlation with neuroendocrine differentiation/grade, but not with other clinicopathologic variables. Further studies appear plausible to elucidate the prognostic significance of GLUT-1 expression in pulmonary carcinoids.

AB - Glucose transporter-1 (GLUT-1) mediates the transport of glucose across the cellular membrane. Its elevated levels and/or activation have been shown to be associated with malignancy. The aim of this study was to investigate GLUT-1 expression in pulmonary neuroendocrine carcinomas. Tissue microarray-based samples of 178 neuroendocrine carcinomas, including 48 typical carcinoids, 31 atypical carcinoids, 27 large cell neuroendocrine carcinomas and 72 small cell carcinomas from different patients, were studied immunohistochemically for GLUT-1 expression. Forty-seven percent (75/161) of pulmonary neuroendocrine carcinomas were immunoreactive with GLUT-1. GLUT-1 was observed in 7% (3/46) of typical carcinoid, 21% (6/29) of atypical carcinoid, 74% (17/23) of large cell neuroendocrine carcinoma and 78% (49/63) of small cell carcinoma. GLUT-1 expression correlated with increasing patient age (P0.01) and with neuroendocrine differentiation/tumor type (P 0.001), but not with gender, tumor size or stage. GLUT-1 expression was seen in a characteristic membranous pattern of staining along the luminal borders or adjacent to necrotic areas. GLUT-1 expression was associated with an increased risk of death for neuroendocrine carcinomas as a group (risk ratio2.519; 95% confidence interval1.519 4.178; P 0.001) and carcinoids (risk ratio4.262; 95% confidence interval1.472 12.343; P0.01). In conclusion, GLUT-1 is expressed in approximately half of the pulmonary neuroendocrine carcinomas and shows a strong correlation with neuroendocrine differentiation/grade, but not with other clinicopathologic variables. Further studies appear plausible to elucidate the prognostic significance of GLUT-1 expression in pulmonary carcinoids.

KW - Carcinoid

KW - GLUT-1

KW - Lung

KW - Neuroendocrine carcinoma

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=67349233033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349233033&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2009.6

DO - 10.1038/modpathol.2009.6

M3 - Article

C2 - 19234439

AN - SCOPUS:67349233033

VL - 22

SP - 633

EP - 638

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 5

ER -